Unicyte Ag

Unicyte AG is a transformative regenerative medicine company advancing stem cell technologies into a novel class of human therapeutics. Unicyte has translated its ground-breaking discoveries into a broad pre-clinical pipeline in key therapeutic areas. The company evolved from a twelve year research collaboration with Prof Giovanni Camussi, a leading expert on extracellular vesicles and stem cells from the University of Turin and Fresenius Medical Care KGaA, the world’s largest provider of products and services for individuals with renal diseases. Unicyte was founded in 2015 as an independent affiliate of Fresenius Medical Care and is headquartered in Oberdorf NW, Switzerland. As a pioneer in liver stem cells and nano-extracellular vesicles the company is dedicated to improving the lives of patients with kidney or liver disease, diabetes, and cancer through its three major technology platforms: » Human Liver Stem Cells » Functional Pancreatic Islets » Nano-Extracellular Vesicles These three proprietary technology platforms are fueling a highly attractive pipeline of therapeutic approaches with profound impact on patients’ lives. Unicyte will pursue its research and pre-clinical programs up until the stage of clinical studies on humans in order to deliver life-changing regenerative medicines in diseases with high unmet need. The company can build on the success of a long standing public private partnership where world-leading science meets excellence in Project and IP Management. This combination has been remarkably effective in advancing a broad portfolio of future therapies towards the clinic and in creating a strong patent portfolio.